title: Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.
abstract: This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10). The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants. At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls. At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls. Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.
authors.affiliation: Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Detopoulou
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fragopoulou
authors.forename: Tzortzis
authors.initials: T
authors.lastname: Nomikos
authors.forename: Smaragdi
authors.initials: S
authors.lastname: Antonopoulou
authors.forename: Iason
authors.initials: I
authors.lastname: Kotroyiannis
authors.forename: Carmen
authors.initials: C
authors.lastname: Vassiliadou
authors.forename: Demosthenes B
authors.initials: DB
authors.lastname: Panagiotakos
authors.forename: Christina
authors.initials: C
authors.lastname: Chrysohoou
authors.forename: Christos
authors.initials: C
authors.lastname: Pitsavos
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
mesh_terms: D000123:Acetyltransferases / Q000378:metabolism*; D000368:Aged; D015415:Biomarkers / Q000378:metabolism*; D002798:Diacylglycerol Cholinephosphotransferase / Q000378:metabolism*; D005500:Follow-Up Studies; D006333:Heart Failure / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D007962:Leukocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010972:Platelet Activating Factor / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D010972:Platelet Activating Factor; D000123:Acetyltransferases; C046035:1-alkylglycerophosphocholine acetyltransferase; D002798:Diacylglycerol Cholinephosphotransferase